Literature DB >> 32620015

Extent of In Utero Transfer of Tenofovir From Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth From a Cohort in the United States.

Jillian Pintye1, Yanling Huo2, Deborah Kacanek2, Kevin Zhang3, Karen Kuncze3, Hideaki Okochi3, Monica Gandhi3.   

Abstract

Understanding in utero transfer of antiretrovirals is critical for interpreting safety. Hair levels measure cumulative exposure. We measured tenofovir (TFV) concentrations in hair at delivery among women living with human immunodeficiency virus receiving TFV disoproxil fumarate-based treatment and their infants, using liquid chromatography-tandem mass spectrometry. Among 103 mother-infant pairs, the mean log10 ratio of infant-to-maternal TFV levels was 1.08 (95% confidence interval, .97-1.20). TFV transfer was 60% lower from mothers who had preterm compared with term deliveries and 42% lower from mothers who had cesarean compared with vaginal deliveries. Like prior studies assessing transfer via short-term measures (plasma, cord blood, amniotic fluid), we found high cumulative transfer using hair.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV/AIDS; antiretroviral therapy; pediatrics; perinatal; pregnancy; tenofovir

Year:  2021        PMID: 32620015      PMCID: PMC7904286          DOI: 10.1093/infdis/jiaa398

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.

Authors:  Catherine A Koss; Albert Y Liu; Jose Castillo-Mancilla; Peter Bacchetti; Cricket McHugh; Karen Kuncze; Mary Morrow; Alexander Louie; Sharon Seifert; Hideaki Okochi; Samantha MaWhinney; Monica Gandhi; Peter L Anderson
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

Review 2.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

3.  Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.

Authors:  Zuzana Neumanova; Lukas Cerveny; Martina Ceckova; Frantisek Staud
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

Review 4.  Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.

Authors:  Lynne M Mofenson; Rachel C Baggaley; Ioannis Mameletzis
Journal:  AIDS       Date:  2017-01-14       Impact factor: 4.177

5.  Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Authors:  Mary G Fowler; Min Qin; Susan A Fiscus; Judith S Currier; Patricia M Flynn; Tsungai Chipato; James McIntyre; Devasena Gnanashanmugam; George K Siberry; Anne S Coletti; Taha E Taha; Karin L Klingman; Francis E Martinson; Maxensia Owor; Avy Violari; Dhayendre Moodley; Gerhard B Theron; Ramesh Bhosale; Raziya Bobat; Benjamin H Chi; Renate Strehlau; Pendo Mlay; Amy J Loftis; Renee Browning; Terence Fenton; Lynette Purdue; Michael Basar; David E Shapiro; Lynne M Mofenson
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

6.  Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse.

Authors:  B Bar-Oz; J Klein; T Karaskov; G Koren
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-03       Impact factor: 5.747

7.  Formation of cornified cell envelope in human hair follicle development.

Authors:  M Akiyama; I Matsuo; H Shimizu
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

8.  Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Authors:  Rosa F Yeh; Naser L Rezk; Angela D M Kashuba; Julie B Dumond; Hiba L Tappouni; Hsiao-Chuan Tien; Ya-Chi Chen; Manoli Vourvahis; Amanda L Horton; Susan A Fiscus; Kristine B Patterson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

9.  Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Authors:  Mark Mirochnick; Taha Taha; Regis Kreitchmann; Karin Nielsen-Saines; Newton Kumwenda; Esau Joao; Jorge Pinto; Breno Santos; Teresa Parsons; Brian Kearney; Lynda Emel; Casey Herron; Paul Richardson; Sarah E Hudelson; Susan H Eshleman; Kathleen George; Mary G Fowler; Paul Sato; Lynne Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

10.  Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.

Authors:  Rebecca Zash; Lewis Holmes; Modiegi Diseko; Denise L Jacobson; Sean Brummel; Gloria Mayondi; Arielle Isaacson; Sonya Davey; Judith Mabuta; Mompati Mmalane; Tendani Gaolathe; M Essex; Shahin Lockman; Joseph Makhema; Roger L Shapiro
Journal:  N Engl J Med       Date:  2019-07-22       Impact factor: 91.245

View more
  1 in total

Review 1.  Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.

Authors:  Randy M Stalter; Jillian Pintye; Kenneth K Mugwanya
Journal:  Expert Opin Drug Saf       Date:  2021-05-28       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.